Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS)

NCT ID: NCT00673140

Last Updated: 2009-08-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-05-31
• Study Completion Date: 2010-06-30

Brief Summary

Amyotrophic Lateral Sclerosis (ALS, sometimes called Lou Gehrig's s Disease, or Maladie de Charcot) is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement.

This study will investigate the use of far infrared radiation for the control, management and treatment of ALS.

Detailed Description

As a motor neuron disease, ALS causes muscle weakness and atrophy throughout the body as both the upper and lower motor neurons degenerate, ceasing to send messages to muscles. Unable to function, the muscles gradually weaken, develop fasciculations (twitches) because of denervation, and eventually atrophy due to that denervation. The patient may ultimately lose the ability to initiate and control all voluntary movement except of the eyes.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have ALS.

Conditions

Amyotrophic Lateral Sclerosis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Group Type: EXPERIMENTAL

Far Infrared Radiation (5μm to 20μm wavelength)

Intervention Type: RADIATION

Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.

Far infrared radiation

Intervention Type: RADIATION

Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.

Interventions

Far Infrared Radiation (5μm to 20μm wavelength)

Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.

Intervention Type: RADIATION

Far infrared radiation

Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.

Intervention Type: RADIATION

Other Intervention Names

Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Eligibility Criteria

Inclusion Criteria

• Patients with ALS

Exclusion Criteria

• None

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GAAD Medical Research Institute Inc.

OTHER

Sponsor Role: lead

Responsible Party

GAAD Medical Research Institute Inc.

Principal Investigators

Ken Nedd, M.D.

Role: PRINCIPAL_INVESTIGATOR

GAAD Medical Research Institute Inc.

Locations

The Centre for Incurable Diseases

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

GAAD-ALS-CTP1

Identifier Type: -

Identifier Source: org_study_id